245 related articles for article (PubMed ID: 18448761)
1. A once-yearly IV bisphosphonate for osteoporosis.
Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761
[No Abstract] [Full Text] [Related]
2. A once-yearly IV bisphosphonate for osteoporosis.
Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
[No Abstract] [Full Text] [Related]
3. Consultation corner. Bone loss drug gives users a break.
Bellantoni M
Johns Hopkins Med Lett Health After 50; 2007 Dec; 19(10):6. PubMed ID: 18225340
[No Abstract] [Full Text] [Related]
4. Annual zoledronic acid for osteoporosis.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
[TBL] [Abstract][Full Text] [Related]
5. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
6. By the way, doctor. Should I take an intravenous drug for osteoporosis?
Robb-Nicholson C
Harv Womens Health Watch; 2007 Jul; 14(11):8. PubMed ID: 17665505
[No Abstract] [Full Text] [Related]
7. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
[TBL] [Abstract][Full Text] [Related]
8. Avascular necrosis of the proximal carpal row of the wrist. A possible complication of bisphosphonate administration.
Didden K; De Smet L; Vandenberghe L; Sciot R; Degreef I
Chir Main; 2012 Dec; 31(6):355-7. PubMed ID: 23177907
[TBL] [Abstract][Full Text] [Related]
9. Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.
Med Lett Drugs Ther; 2009 Jun; 51(1315):49. PubMed ID: 19556940
[No Abstract] [Full Text] [Related]
10. New annual osteoporosis drug reduces risk of death, future fractures. Infused dose is more convenient for patients, enhances overall quality of life.
Duke Med Health News; 2007 Dec; 13(12):8. PubMed ID: 18286732
[No Abstract] [Full Text] [Related]
11. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
Ringe JD
MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
[No Abstract] [Full Text] [Related]
12. [New bone density conservation agents for osteoporosis under research and development: Zoledronate].
Wada S; Fukawa T; Kamiya S
Nihon Rinsho; 2007 Nov; 65 Suppl 9():421-5. PubMed ID: 18161143
[No Abstract] [Full Text] [Related]
13. Zoledronic acid--once-yearly. Corticosteroid-induced osteoporosis: no benefit.
Prescrire Int; 2010 Apr; 19(106):63. PubMed ID: 20568485
[No Abstract] [Full Text] [Related]
14. What do we know about the ocular adverse effects associated with intravenous bisphosphonates?
Atik OS
Eklem Hastalik Cerrahisi; 2011; 22(1):1. PubMed ID: 21417978
[No Abstract] [Full Text] [Related]
15. Sore mandible. Bisphosphonate-associated osteonecrosis.
Damm DD; Fantasia JE
Gen Dent; 2006; 54(5):370, 372. PubMed ID: 17004575
[No Abstract] [Full Text] [Related]
16. [Osteoporosis and bisphosphonates].
Zuber MA
Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
[No Abstract] [Full Text] [Related]
17. Atrial fibrillation following intravenous zolendronic acid for osteoporosis.
Konsta M; Bournia VK; Dania V; Iliopoulos A
J Clin Rheumatol; 2014 Jun; 20(4):239-40. PubMed ID: 24847757
[No Abstract] [Full Text] [Related]
18. To treat osteoporosis, Denosumab appears more effective than Zoledronate. Denosumab has the advantage in building bone density, and has fewer side effects.
Duke Med Health News; 2014 Mar; 20(3):1-2. PubMed ID: 24683617
[No Abstract] [Full Text] [Related]
19. [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].
Ringe JD; Nitschmann S
Internist (Berl); 2008 Apr; 49(4):502-4. PubMed ID: 18305914
[No Abstract] [Full Text] [Related]
20. [Bisphosphonate therapy for osteoporosis and bone strength].
Kishimoto H
Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]